A Review on Pathophysiology, Virulence, and Prophylactic Vaccination of Meningococcal Disease

Review article

Authors

  • Dr. Syed Ansar Ahmed Department of Pharmaceutical Chemistry, Indira College of Pharmacy, Vishnupuri, Nanded, Maharashtra, India Author
  • Amol Pandit Chavan Department of Pharmaceutical Chemistry, Indira College of Pharmacy, Vishnupuri, Nanded, Maharashtra, India Author
  • Dashrath Limbaji Chavan Department of Pharmaceutical Chemistry, Indira College of Pharmacy, Vishnupuri, Nanded, Maharashtra, India Author
  • Akanksha Vijay Chonde Department of Pharmaceutical Chemistry, Indira College of Pharmacy, Vishnupuri, Nanded, Maharashtra, India Author
  • Asha Gangadhar Dakore Department of Pharmaceutical Chemistry, Indira College of Pharmacy, Vishnupuri, Nanded, Maharashtra, India Author

DOI:

https://doi.org/10.69613/g1jar134

Keywords:

Neisseria meningitidis, Pathogenesis, Meningococcemia, Bacterial Meningitis, Conjugate Vaccines

Abstract

Meningococcal disease is a devastating bacterial infection characterized by rapid clinical progression, profound morbidity, and high mortality rates. Caused by the Gram-negative diplococcus Neisseria meningitidis, the pathogen colonizes the human nasopharynx as an asymptomatic commensal before occasionally penetrating the mucosal barrier to cause invasive infections such as meningitis and septicemia. Endothelial damage, intravascular thrombosis, and subsequent circulatory collapse are primarily driven by the systemic release of bacterial endotoxins. Diagnostic confirmation depends on lumbar puncture for cerebrospinal fluid analysis, blood cultures, and polymerase chain reaction assays, which facilitate rapid pathogen identification. Prompt administration of empirical intravenous antibiotics, combined with supportive critical care, is crucial to mitigate severe neurological sequelae and fatal outcomes. However, prophylactic vaccination represents the most sustainable strategy for long-term control. The development of vaccines has progressed from early capsular polysaccharide formulations to advanced conjugate vaccines, which elicit robust T-cell dependent immunological memory and reduce nasopharyngeal carriage. Protein-based vaccines have successfully addressed the low immunogenicity of the serogroup B capsular polysaccharide, while novel pentavalent formulations offer consolidated protection against multiple virulent serogroups. Implementing structured national immunization schedules, prioritizing high-risk cohorts such as infants, adolescents, and travelers, and maintaining rigorous disease surveillance systems are paramount to reducing the global burden. Ensuring equitable vaccine access in resource-limited regions, particularly within highly endemic geographical zones, remains a critical public health objective to control and eventually eliminate the threat of invasive meningococcal disease worldwide.

Downloads

Download data is not yet available.

Downloads

Published

05-04-2026

Issue

Section

Articles

How to Cite

A Review on Pathophysiology, Virulence, and Prophylactic Vaccination of Meningococcal Disease: Review article. (2026). Journal of Pharma Insights and Research, 4(2), 347-369. https://doi.org/10.69613/g1jar134

Similar Articles

1-10 of 46

You may also start an advanced similarity search for this article.